Company environment · Targeted small molecules · FDA CDER
Rare-oncology NDA & supplemental sNDA sequence freezes
Initial NDA and supplemental sNDA eCTD sequence freezes.
1What does this company do?
Oncology sponsor managing initial NDA and serial sNDA efficacy supplements for a targeted kinase inhibitor in rare tumors.
2Where is the product on its way to patients?
Oral kinase inhibitor across initial NDA approval and subsequent sNDA indication expansions.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- The product is here
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
3What is happening right now?
An eCTD sequence freeze gate is open, and working clinical, labeling, and CMC leaves contain unresolved discrepancies.
4Tasks
5 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →